InvestSMART

Orthocell Limited (ASX: OCC) - Share Price

Current share price for OCC : $0.570 0.02 (3.64%)+

Orthocell Limited (OCC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It operates as a regenerative medicine company engaged in developing products for the repair of bone and soft tissue injuries. The company has appointed a network of specialist distributors in the United States and recorded initial sales. The company's nerve repair product holds approval in Australia, New Zealand and Singapore and is distributed through Device Technologies Group in those markets.

OCC General Information +

ASX Code OCC
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 155
OCC Share Price $0.570
Day High $0.570
Day Low $0.535
Last Close $0.550
OCC Share Price Movement $0.02 ( 3.64% )
Prices as at 16:40, 20 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Orthocell Limited (OCC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Orthocell Limited (OCC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Orthocell Limited (OCC) price-sensitive announcements

OCC - Marine Biomedical Achieves FDA Clearance
Orthocell announced that its strategic partner Marine Biomedical Pty Ltd has received U.S.
Orthocell Limited (OCC)
3 Nov 2026 | 10:09 AM
OCC - Strongest U.S. Remplir Sales Month Since Launch
Orthocell announced that its U.S. nerve repair product Remplir achieved its strongest sale
Orthocell Limited (OCC)
2 Nov 2026 | 8:32 AM
OCC - Q1 FY27 OCC Investor Presentation
Orthocell Limited’s Q1 FY27 investor presentation outlines growing commercial traction for
Orthocell Limited (OCC)
22 Oct 2026 | 9:00 AM
OCC - Quarterly Activity Report & Appendix 4C
Orthocell Limited’s September 2026 quarterly report and Appendix 4C show the company conti
Orthocell Limited (OCC)
22 Oct 2026 | 8:57 AM

Orthocell Limited (OCC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Orthocell Limited (OCC)
ORDINARY FULLY PAID
Health Care $155 Appendix 3Y - Michael McNulty 13 Nov 2026 8:25AM $0.575 $0.570 fallen by 0.87%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
Health Care $155 Notification regarding unquoted securities - OCC 10 Nov 2026 6:17PM $0.595 $0.570 fallen by 4.20%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
Health Care $155 Option Terms and Conditions 10 Nov 2026 2:55PM $0.590 $0.570 fallen by 3.39%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
Health Care $155 Proposed issue of securities - OCC 10 Nov 2026 2:52PM $0.590 $0.570 fallen by 3.39%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
Health Care $155 Appendix 3Y - John Van Der Wielen 10 Nov 2026 8:57AM $0.590 $0.570 fallen by 3.39%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
Health Care $155 Amended Constitution 6 Nov 2026 4:19PM $0.575 $0.570 fallen by 0.87%

OCC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2028F C2 -$2.00 -60.00% 0.00 0.00 0.00% 0.0%
2027F C2 -$5.00 -2.70% 0.00 0.00 0.00% 0.0%
2026A -$13.53 -$5.10 33.90% 0.00 0.00 0.00% 0.0%

OCC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2026 A 2027 F 2028 F 2026 A 2027 F 2028 F 2026 A 2027 F 2028 F
CSL Limited (CSL) $95,905M 0.7309 -0.4349 0.0602 12.3811 21.9110 20.6672 2.13% 2.15% 2.22%
Mesoblast Limited (MSB) $2,219M -0.4501 0.0000 0.0000 0.0000 0.0000 775.0000 0.00% 0.00% 0.00%
Orthocell Limited (OCC) $150M 0.3385 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,605M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,499M -1.3893 0.0000 -0.5234 0.0000 154.4393 324.0196 0.00% 0.00% 0.00%

OCC Directors

Name Position Start Date
Mr Paul Frederick Anderson Chief Executive Officer, Managing Director 21 Mar 2006
Dr Ravi Thadhani Lead Independent Director, Non-Executive Director 8 Mar 2023
Mr John Van Der Wielen Non-Executive Chairman, Non-Executive Director 1 Jun 2023
Professor Fiona Melanie Wood Non-Executive Director 1 Nov 2023
Mr Michael McNulty Non-Executive Director 1 Sep 2025

Orthocell Limited (OCC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
10 Nov 2026 MCNULTY, Michael Buy Indirect Shares 74,548 $0.599 $44,630.460
9 Nov 2026 WIELEN, John Buy Indirect Shares 90,000 $0.594 $53,420.740
20 Jul 2026 WIELEN, John Issued Direct Shares 15,430 $0.756 $11,666.670

See all changes in directors' interest & trades for Orthocell Limited (OCC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

OCC Management

Name Position
Jim Piper CFO
Peter Webse Company Secretary
Alex McHenry COO

OCC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Orthocell Limited (OCC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
0 (0%) n/a

OCC Calendar of Events

Date Event
30 August 2027 Report (Annual)
30 August 2027 Report (Prelim)
23 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.